本帖最后由 tim889 于 2022-9-21 15:54 编辑
"with three new clinical studies expected to start and new therapeutic HBV Phase 2 data expected before the end of 2022."
VBI-2601 (BRII-179): HBV Immunotherapeutic Candidate - Year-end 2022: Interim topline data expected from Phase 2 human proof of concept combination study evaluating safety and efficacy of VBI-2601 (BRII-179) with BRII-835 (VIR-2218), an HBV-targeting siRNA
- H1 2023: Interim topline results expected from two-part Phase 2a/2b combination study evaluating VBI-2601 (BRII-179) as an add-on therapy to standard-of-care treatment
今年美肝会应该会有更多数据 |